IN2012DN06432A - - Google Patents
Info
- Publication number
- IN2012DN06432A IN2012DN06432A IN6432DEN2012A IN2012DN06432A IN 2012DN06432 A IN2012DN06432 A IN 2012DN06432A IN 6432DEN2012 A IN6432DEN2012 A IN 6432DEN2012A IN 2012DN06432 A IN2012DN06432 A IN 2012DN06432A
- Authority
- IN
- India
- Prior art keywords
- cells
- formula
- mammalian cells
- cardiomyocyte
- radicals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ATA2044/2009A AT509266B1 (de) | 2009-12-28 | 2009-12-28 | Substituierte pyridine und pyrimidine |
| PCT/AT2010/000495 WO2011079343A2 (en) | 2009-12-28 | 2010-12-28 | Substituted pyridines and pyrimidines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN06432A true IN2012DN06432A (enExample) | 2015-10-09 |
Family
ID=43825275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN6432DEN2012 IN2012DN06432A (enExample) | 2009-12-28 | 2010-12-28 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8986994B2 (enExample) |
| EP (1) | EP2519501B1 (enExample) |
| AT (1) | AT509266B1 (enExample) |
| IN (1) | IN2012DN06432A (enExample) |
| WO (1) | WO2011079343A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT511441B1 (de) | 2011-09-21 | 2012-12-15 | Univ Wien Tech | Triazin-derivate als differenzierungsbeschleuniger |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| JP6997197B2 (ja) | 2017-01-23 | 2022-01-17 | カデント セラピューティクス，インコーポレーテッド | カリウムチャネルモジュレーター |
| EP3612181A4 (en) | 2017-04-21 | 2021-01-06 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| MX2021004647A (es) | 2018-10-22 | 2021-08-16 | Novartis Ag | Formas cristalinas de moduladores de los canales de potasio. |
| KR20250152723A (ko) * | 2024-04-16 | 2025-10-24 | 경북대학교 산학협력단 | 신규한 피리미딘 유도체 화합물 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10063173A1 (de) * | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
| TWI312347B (en) * | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| JP4510442B2 (ja) * | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20050209231A1 (en) | 2004-01-16 | 2005-09-22 | Xu Wu | Compositions and methods for inducing cardiomyogenesis |
| GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| AU2005289426A1 (en) * | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
-
2009
- 2009-12-28 AT ATA2044/2009A patent/AT509266B1/de not_active IP Right Cessation
-
2010
- 2010-12-28 EP EP20100803206 patent/EP2519501B1/en not_active Not-in-force
- 2010-12-28 WO PCT/AT2010/000495 patent/WO2011079343A2/en not_active Ceased
- 2010-12-28 IN IN6432DEN2012 patent/IN2012DN06432A/en unknown
- 2010-12-28 US US13/519,690 patent/US8986994B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011079343A3 (en) | 2011-10-13 |
| EP2519501B1 (en) | 2015-04-22 |
| EP2519501A2 (en) | 2012-11-07 |
| AT509266B1 (de) | 2014-07-15 |
| AT509266A1 (de) | 2011-07-15 |
| WO2011079343A2 (en) | 2011-07-07 |
| US20120294835A1 (en) | 2012-11-22 |
| US8986994B2 (en) | 2015-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161199A (en) | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 | |
| IN2012DN06432A (enExample) | ||
| NZ741985A (en) | Prodrugs of fumarates and their use in treating various diseases | |
| MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
| MX2012000973A (es) | Compuestos para la reduccion de produccion de beta- amiloide. | |
| MX2010012298A (es) | Activadores de glucocinasa. | |
| PL2231568T3 (pl) | Sposób wytwarzania etanolu z kwasu etanowego i wodoru | |
| MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| IN2014CN03265A (enExample) | ||
| PH12012502128B1 (en) | Chemical compounds | |
| MX2009012623A (es) | Moduladores de cinasa heterociclicos. | |
| UA91895C2 (en) | Thiazole compounds and methods of use | |
| GB0920703D0 (en) | Compositions containing satiogens and methods of use | |
| MY171831A (en) | Novel fused pyrimidine compound or salt thereof | |
| DK1999160T3 (da) | Acryleret hyaluronsyre | |
| TN2012000578A1 (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| PH12013501089A1 (en) | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 | |
| TN2013000400A1 (en) | Imidazopyridazines as akt kinase inhibitors | |
| MX2009011255A (es) | Proceso para preparar capecitabina. | |
| MX2014002936A (es) | Nuevos derivados de acido betulinico con actividad antiviral. | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| AU2011208681A8 (en) | Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
| IN2015DN03751A (enExample) | ||
| CA2837895C (en) | Methods of treating or preventing neurological diseases |